CFRXQ.US ContraFect Corporation

Healthcare Biotechnology USA Stocks
0.0000 USD
Close of Nov 13, 2026
Market cap
USD 107.00
P/E
-
P/B
0.44x
ROE
-
Dividend yield
-
Fundamental score
-

Is CFRXQ.US undervalued?

Graham number

The Graham number of ContraFect Corporation cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

ContraFect Corporation fundamental analysis

No fundamental analysis for ContraFect Corporation yet.

ContraFect Corporation stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About ContraFect Corporation

ContraFect Corporation, a clinical-stage biotechnology company, discovers and develops therapeutic protein and antibody products for the treatment of life-threatening and drug-resistant infectious diseases in the United States. Its lead program includes Exebacase, a lysin, which is in Phase III clinical trials for the treatment of staphylococcus aureus. The company also developing CF-370, an investigational anti-bacterial therapeutic candidate, which is in Phase 1 clinical t…

Full company profile